FOSTER CITY, CA - March 19, 1998 - DepoMed, Inc. (Nasdaq: DPMD) reported revenues of $605,000 for the year ended December 31, 1997, resulting from research and development payments in connection with its ongoing development work with Bristol-Myers Squibb. Revenues were $318,000 in 1996.
FOSTER CITY, CA - March 4, 1998 - DepoMed, Inc. (Nasdaq: DPMD) announced that it has entered into a research collaboration with the R. W. Johnson Pharmaceutical Research Institute (PRI), a Johnson & Johnson unit, to study the feasibility of an orally administered, controlled release pharmaceutical
FOSTER CITY, CA - February 24, 1998 - DepoMed, Inc. (Nasdaq: DPMD) announced that it has completed a private placement of common stock for $8 million, with net proceeds of approximately $7.5 million to the Company. Investors agreed to a lock-up provision until November 6th, 1998, the one-year
FOSTER CITY, CA - February 12, 1998 - DepoMed, Inc. today announced that Dr. W. Leigh Thompson was elected to the Board of Directors on January 30, 1998. Dr. Thompson (59) was previously Chief Scientific Officer at Eli Lilly before founding Profound Quality Resources, Ltd., a private healthcare
FOSTER CITY, CA - December 1, 1997 - DepoMed, Inc. (Nasdaq: DPMDU) today announced that, effective December 1, 1997, the Common Stock and Warrants comprising the Company's Units will become detachable and separately transferable. Also effective as of December 1, 1997, the shares of Common Stock and
FOSTER CITY, CA - November 5, 1997 -- DepoMed, Inc. today announced its initial public offering of 1,200,000 Units (each Unit consisting of one share of common stock and one common stock purchase warrant), at a price of $6.10 per Unit. The Units are quoted on the Nasdaq Small Cap Market under the